Leap Therapeutics DKN-01 gets FDA fast track designation for gastric and gastroesophageal junction cancer

Leap Therapeutics

The FDA granted Leap Therapeutics’ (NASDAQ:LPTX) DKN-01 fast track designation for gastric and gastroesophageal junction cancer.

Specifically, the designation was granted for patients whose tumors express high Dickkopf-1 protein and who have experienced disease progression on or after chemotherapy and, if appropriate, HER2-targeted therapy.

Leap recently dosed the first patient with gastric or gastroesophageal junction cancer in a combination study of DKN-01 plus tislelizumab, an anti-PD-1 antibody.

“The designation highlights the existing unmet medical need for new and effective treatments for this patient population,” Douglas Onsi, Leap’s president and CEO, said in a statement. 

“We believe that DKN-01 shows promise as a novel treatment option for biomarker-selected patients with these cancers, and this designation provides us with earlier and more frequent opportunities to interact with the FDA during the development of DKN-01,” he added.

DKN-01 received FDA orphan drug designation for the treatment of gastric and gastroesophageal junction cancer in June 2020.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.